Institutional members access full text with Ovid®

Labeling Changes for Topiramate (Topamax) and Doripenem (Doribax)

Aschenbrenner, Diane S. MS, RN

AJN, American Journal of Nursing: July 2014 - Volume 114 - Issue 7 - p 22–23
doi: 10.1097/01.NAJ.0000451677.35953.ab
Drug Watch

* The Food and Drug Administration (FDA) has approved the antiepileptic drug topiramate (Topamax) for a new indication, the prevention of migraines in adolescents ages 12 to 17.

* The FDA has added a new warning to the labeling of the antibiotic doripenem (Doribax), which now warns that the drug increases the risk of death if used to treat ventilator-associated bacterial pneumonia, an off-label use.

© 2014 Lippincott Williams & Wilkins. All rights reserved.